Is Cyclerion Therapeutics Inc halal to invest in?

According to Musaffa's Shariah screening methodology, Cyclerion Therapeutics Inc (CYCN) is currently classified as NOT HALAL as of April 2026. The classification is based on an evaluation of the company's business activities and financial ratios to determine whether it meets Islamic investment guidelines.

Is Cyclerion Therapeutics Inc a Shariah-compliant stock?

A stock is Shariah-compliant if the company operates in permissible business activities and meets Islamic financial screening thresholds. Musaffa analyzes Cyclerion Therapeutics Inc using these criteria to determine its compliance status.

Can Muslims buy shares of Cyclerion Therapeutics Inc?

Muslim investors may consider investing in Cyclerion Therapeutics Inc if it meets Shariah compliance standards. Investors typically review the company's business activities, debt levels, and non-permissible income before making a decision.

Why is Cyclerion Therapeutics Inc classified as NOT HALAL?

Musaffa determines the Shariah status of Cyclerion Therapeutics Inc by analyzing whether the company's core business operations are permissible and whether its financial ratios fall within accepted Islamic thresholds.

How often is the Shariah compliance for Cyclerion Therapeutics Inc updated?

The Shariah compliance status of Cyclerion Therapeutics Inc may be updated periodically when new financial statements, earnings reports, or business activity information become available.

Can a halal stock like Cyclerion Therapeutics Inc become non-compliant?

Yes. A stock that is currently Shariah-compliant may become non-compliant if the company's financial ratios exceed Shariah thresholds or its business activities change.

Where can I check the Shariah status of Cyclerion Therapeutics Inc?

You can check the latest Shariah compliance status of Cyclerion Therapeutics Inc on Musaffa's stock page, where screening results and key financial indicators are updated to help Muslim investors make informed decisions.

CYCN Shariah Compliance

Screening Methodology: AAOIFI

NOT HALAL

Last Updated: April 03, 2026

Report Source: 2025 Annual Report

Analyst's Ratings for Cyclerion Therapeutics Inc (CYCN)

Based on 7 analysts giving stock ratings to Cyclerion Therapeutics Inc in the past 3 months

Strong
SellSellHoldBuyStrong
Buy

Strong Buy

Buy

Hold

Sell

Strong Sell

Cyclerion Therapeutics Inc. Stock Analysis CYCN

United States Health Care Nano Cap Report: 2025 Annual

Cyclerion Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the discovery, development, and commercialization of human therapeutics. The company is headquartered in Cambridge, Massachusetts and currently employs 1 full-time employees. The company went IPO on 2019-03-18. The firm is focused on building a pipeline with therapeutics to treat certain neuropsychiatric diseases. The company is focused on an individualized therapy for treatment-resistant depression (TRD) - a condition with significant unmet medical need. Its assets include Olinciguat and Praliciguat. The firm has entered into an exclusive license option agreement for its vascular soluble guanylate cyclase (sGC) stimulator, olinciguat. Praliciguat is an oral, once-daily, systemic sGC stimulator that is licensed to Akeibia Therapeutics, Inc and is being advanced in rare kidney disease.

Key Statistics of Cyclerion Therapeutics Inc (CYCN)

Key statistics in the stock market are essential financial indicators that measure a company's performance, valuation, profitability, and risk.

Today's Range

$3.06$3.17

Today's Open

$3.06

Volume

51.81K

P/E Ratio (TTM)

52 Week Range

$1.03$8.48

Market Cap

13.64M

Avg. Volume

119.54K

Dividend Yield

Financial Metrics & Statements of Cyclerion Therapeutics Inc (CYCN)

FAQ's for Cyclerion Therapeutics Inc (CYCN)

According to Musaffa’s Shariah screening methodology, Cyclerion Therapeutics Inc (CYCN) is currently classified as NOT HALAL as of April 2026. The classification is based on an evaluation of the company’s business activities and financial ratios to determine whether it meets Islamic investment guidelines.